# Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

> **NCT00981162** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Acinar Cell Adenocarcinoma of the Pancreas
- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** everolimus
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacogenomic studies
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00981162
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-08
- **Final completion:** 2012-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981162, "Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00981162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*